Nano Research

, Volume 9, Issue 11, pp 3305–3321 | Cite as

Synergy and translation of allogenic bone marrow stem cells after photodynamic treatment of rheumatoid arthritis with tetra sulfonatophenyl porphyrin and TiO2 nanowhiskers

  • Fawad U. Rehman
  • Chunqiu Zhao
  • Changyu Wu
  • Xiaoqi Li
  • Hui Jiang
  • Matthias Selke
  • Xuemei WangEmail author
Research Article


Rheumatoid arthritis (RA) etiology and amelioration remains a challenge in modern therapeutics. Herein, we explored the synergistic effect of allogenic bone marrow stem cell (BMSC) translation and photodynamic treatment of RA with tetra sulfonatophenyl porphyrin (TSPP) and TiO2 nanocomposites as a new strategy for RA theranostics. The translation of BMSCs with miRNAs into infected joints in long bones post-photodynamic therapy is helpful for treating and understanding RA pathophysiology. We observed that allogenic BMSC translation combined with TSPP-TiO2 nanocomposites can significantly (p < 0.01) lower the concentrations of serum biomarkers (tumor necrosis factor-α and interleukin-17) in a collagen induced arthritis (CIA) murine model, both in vitro and in vivo, as well as improve other parameters such as arthritis score, BMSC count, complete blood count, and numbers of platelets, red blood cells, and white blood cells. Moreover, a fluorescent TSPP in the feet or long bones and X-ray bioimaging of RA joints revealed the clinical efficacy of BMSCs combined with TSPP-TiO2 nanocomposites. Microarray data analysis illustrated that rno-mir-375-3p and rno-mir-196b-3p were up-regulated by approximately 100-fold in the BMSCs of ameliorated RA post-photodynamic therapy with TSPP-TiO2 nanocomposites. Our study not only suggests a new approach for RA theranostics, but also helps in understanding RA pathophysiology.


rheumatoid arthritis allogenic bone marrow stem cells (BMSCs) tetra sulfonatophenyl porphyrin (TSPP)-TiO2 nanocomposites photodynamic treatment miRNAs 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

12274_2016_1208_MOESM1_ESM.pdf (2.2 mb)
Synergy and translation of allogenic bone marrow stem cells after photodynamic treatment of rheumatoid arthritis with tetra sulfonatophenyl porphyrin and TiO2 nanowhiskers


  1. [1]
    United Nations. Prevention and control of non-communicable diseases. Report of the Secretary-General. New York: United Nations, 2011.Google Scholar
  2. [2]
    Schuna, A. A. Update on treatment of rheumatoid arthritis. J. Am. Pharm. Assoc. (Wash.) 1998, 38, 728–735; quiz 735–737.CrossRefGoogle Scholar
  3. [3]
    Rudan, I.; Sidhu, S.; Papana, A.; Meng, S. J.; Xin–Wei, Y.; Wang, W.; Campbell–Page, R. M.; Demaio, A. R.; Nair, H.; Sridhar, D. et al. Prevalence of rheumatoid arthritis in low-and middle-income countries: A systematic review and analysis. J. Glob. Health 2015, 5, 010409.CrossRefGoogle Scholar
  4. [4]
    Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423, 356–361.CrossRefGoogle Scholar
  5. [5]
    Chen, L. J.; Bao, B.; Wang, N. P.; Xie, J.; Wu, W. H. Oral administration of shark type II collagen suppresses complete Freund’s adjuvant-induced rheumatoid arthritis in rats. Pharmaceuticals 2012, 5, 339–352.CrossRefGoogle Scholar
  6. [6]
    Brennan, F. M.; Maini, R. N.; Feldmann, M. TNFα—A pivotal role in rheumatoid arthritis? Rheumatology 1992, 31, 293–298.CrossRefGoogle Scholar
  7. [7]
    Chabaud, M.; Durand, J. M.; Buchs, N.; Fossiez, F.; Page, G.; Frappart, L.; Miossec, P. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999, 42, 963–970.CrossRefGoogle Scholar
  8. [8]
    Ziolkowska, M.; Koc, A.; Luszczykiewicz, G.; Ksiezopolska-Pietrzak, K.; Klimczak, E.; Chwalinska-Sadowska, H.; Maslinski, W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 2000, 164, 2832–2838.CrossRefGoogle Scholar
  9. [9]
    Grove, J. E.; Bruscia, E.; Krause, D. S. Plasticity of bone marrow-derived stem cells. Stem Cells 2004, 22, 487–500.CrossRefGoogle Scholar
  10. [10]
    Taichman, R. S. Blood and bone: Two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005, 105, 2631–2639.CrossRefGoogle Scholar
  11. [11]
    Zappia, E.; Casazza, S.; Pedemonte, E.; Benvenuto, F.; Bonanni, I.; Gerdoni, E.; Giunti, D.; Ceravolo, A.; Cazzanti, F.; Frassoni, F. et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106, 1755–1761.CrossRefGoogle Scholar
  12. [12]
    Liu, C.-H.; Hwang, S.-M. Cytokine interactions in mesenchymal stem cells from cord blood. Cytokine 2005, 32, 270–279.CrossRefGoogle Scholar
  13. [13]
    Maitra, B.; Szekely, E.; Gjini, K.; Laughlin, M. J.; Dennis, J.; Haynesworth, S. E.; Koc, O. N. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004, 33, 597–604.CrossRefGoogle Scholar
  14. [14]
    Potian, J. A.; Aviv, H.; Ponzio, N. M.; Harrison, J. S.; Rameshwar, P. Veto-like activity of mesenchymal stem cells: Functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 2003, 171, 3426–3434.CrossRefGoogle Scholar
  15. [15]
    Di Nicola, M.; Carlo-Stella, C.; Magni, M.; Milanesi, M.; Longoni, P. D.; Matteucci, P.; Grisanti, S.; Gianni, A. M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99, 3838–3843.CrossRefGoogle Scholar
  16. [16]
    Yoshida, Y.; Takahashi, K.; Okita, K.; Ichisaka, T.; Yamanaka, S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009, 5, 237–241.CrossRefGoogle Scholar
  17. [17]
    Bartel, D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297.CrossRefGoogle Scholar
  18. [18]
    He, L.; He, X. Y.; Lowe, S. W.; Hannon, G. J. MicroRNAs join the p53 network—Another piece in the tumoursuppression puzzle. Nat. Rev. Cancer 2007, 7, 819–822.CrossRefGoogle Scholar
  19. [19]
    Esau, C.; Davis, S.; Murray, S. F.; Yu, X. X.; Pandey, S. K.; Pear, M.; Watts, L.; Booten, S. L.; Graham, M.; McKay, R. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3, 87–98.CrossRefGoogle Scholar
  20. [20]
    Chen, C.-Z.; Li, L.; Lodish, H. F.; Bartel, D. P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303, 83–86.CrossRefGoogle Scholar
  21. [21]
    Callis, T. E.; Chen, J.-F.; Wang, D.-Z. MicroRNAs in skeletal and cardiac muscle development. DNA Cell Biol. 2007, 26, 219–225.CrossRefGoogle Scholar
  22. [22]
    Calin, G. A.; Ferracin, M.; Cimmino, A.; Di Leva, G.; Shimizu, M.; Wojcik, S. E.; Iorio, M. V.; Visone, R.; Sever, N. I.; Fabbri, M. et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353, 1793–1801.CrossRefGoogle Scholar
  23. [23]
    Hanson, E. K.; Lubenow, H.; Ballantyne, J. Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal. Biochem. 2009, 387, 303–314.CrossRefGoogle Scholar
  24. [24]
    Mitchell, P. S.; Parkin, R. K.; Kroh, E. M.; Fritz, B. R.; Wyman, S. K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; O'Briant, K. C.; Allen, A. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518.CrossRefGoogle Scholar
  25. [25]
    Stanczyk, J.; Pedrioli, D. M. L.; Brentano, F.; Sanchez-Pernaute, O.; Kolling, C.; Gay, R. E.; Detmar, M.; Gay, S.; Kyburz, D. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58, 1001–1009.CrossRefGoogle Scholar
  26. [26]
    Nakamachi, Y.; Kawano, S.; Takenokuchi, M.; Nishimura, K.; Sakai, Y.; Chin, T.; Saura, R.; Kurosaka, M.; Kumagai, S. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblastlike synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 2009, 60, 1294–1304.CrossRefGoogle Scholar
  27. [27]
    Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic therapy. J. Natl. Cancer Inst. 1998, 90, 889–905.CrossRefGoogle Scholar
  28. [28]
    Lucky, S. S.; Soo, K. C.; Zhang, Y. Nanoparticles in photodynamic therapy. Chem. Rev. 2015, 115, 1990–2042.CrossRefGoogle Scholar
  29. [29]
    Zhao, C. Q.; Ur Rehman, F.; Yang, Y. L.; Li, X. Q.; Zhang, D.; Jiang, H.; Selke, M.; Wang, X. M.; Liu, C. Y. Bio-imaging and photodynamic therapy with tetra sulphonatophenyl porphyrin (TSPP)-TiO2 nanowhiskers: New approaches in rheumatoid arthritis theranostics. Sci. Rep. 2015, 5, 11518.CrossRefGoogle Scholar
  30. [30]
    Rehman, F. U.; Zhao, C. Q.; Wu, C. Y.; Jiang, H.; Selke, M.; Wang, X. M. Influence of photoactivated tetra sulphonatophenyl porphyrin and TiO2 nanowhiskers on rheumatoid arthritis infected bone marrow stem cell proliferation in vitro and oxidative stress biomarkers in vivo. RSC Adv. 2015, 5, 107285–107292.CrossRefGoogle Scholar
  31. [31]
    Benov, L.; Batinic-Haberle, I. A manganese porphyrin suppresses oxidative stress and extends the life span of streptozotocin-diabetic rats. Free Radic. Res. 2005, 39, 81–88.CrossRefGoogle Scholar
  32. [32]
    Chu, Z. Q.; Zhang, S.; Yin, C.; Lin, G.; Li, Q. Designing nanoparticle carriers for enhanced drug efficacy in photodynamic therapy. Biomater. Sci. 2014, 2, 827–832.CrossRefGoogle Scholar
  33. [33]
    Rehman, F. U.; Zhao, C. Q.; Jiang, H.; Selke, M.; Wang, X. M. Protective effect of TiO2 nanowhiskers on tetra sulphonatophenyl porphyrin (TSPP) complexes induced oxidative stress during photodynamic therapy. Photodiagnosis Photodyn. Ther. 2016, 13, 267–275.CrossRefGoogle Scholar
  34. [34]
    Cai, R. X.; Hashimoto, K.; Itoh, K.; Kubota, Y.; Fujishima, A. Photokilling of malignant cells with ultrafine TiO2 powder. Bull. Chem. Soc. Jpn. 1991, 64, 1268–1273.CrossRefGoogle Scholar
  35. [35]
    Rehman, F. U.; Zhao, C.; Jiang, H.; Wang, X. Biomedical applications of nano-titania in theranostics and photodynamic therapy. Biomater. Sci. 2016, 4, 40–54.CrossRefGoogle Scholar
  36. [36]
    Zhang, S. C.; Yang, D. J.; Jing, D. W.; Liu, H. W.; Liu, L.; Jia, Y.; Gao, M. H.; Guo, L. J.; Huo, Z. Y. Enhanced photodynamic therapy of mixed phase TiO2(B)/anatase nanofibers for killing of HeLa cells. Nano Res. 2014, 7, 1659–1669.CrossRefGoogle Scholar
  37. [37]
    Jimenez-Boj, E.; Redlich, K.; Türk, B.; Hanslik-Schnabel, B.; Wanivenhaus, A.; Chott, A.; Smolen, J. S.; Schett, G. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J. Immunol. 2005, 175, 2579–2588.CrossRefGoogle Scholar
  38. [38]
    Sekiya, I.; Larson, B. L.; Smith, J. R.; Pochampally, R.; Cui, J. G.; Prockop, D. J. Expansion of human adult stem cells from bone marrow stroma: Conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002, 20, 530–541.CrossRefGoogle Scholar
  39. [39]
    De Jong, W. H.; Borm, P. J. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine 2008, 3, 133–149.CrossRefGoogle Scholar
  40. [40]
    Ruan, C. H.; Zhang, L. F.; Qin, Y. L.; Xu, C.; Zhang, X. B.; Wan, J. M.; Peng, Z. G.; Shi, J. J.; Li, X. Y.; Wang, L. Synthesis of porphyrin sensitized TiO2/graphene and its photocatalytic property under visible light. Mater. Lett. 2015, 141, 362–365.CrossRefGoogle Scholar
  41. [41]
    Rahimi, R.; Zargari, S.; Yousefi, A.; Berijani, M. Y.; Ghaffarinejad, A.; Morsali, A. Visible light photocatalytic disinfection of E. coli with TiO2–graphene nanocomposite sensitized with tetrakis (4-carboxyphenyl) porphyrin. Appl. Surf. Sci. 2015, 355, 1098–1106.CrossRefGoogle Scholar
  42. [42]
    Zargari, S.; Rahimi, R.; Yousefi, A. An efficient visible light photocatalyst based on tin porphyrin intercalated between TiO2–graphene nanosheets for inactivation of E. coli and investigation of charge transfer mechanism. RSC Adv. 2016, 6, 24218–24228.CrossRefGoogle Scholar
  43. [43]
    Bhaumik, J.; Mittal, A. K.; Banerjee, A.; Chisti, Y.; Banerjee, U. C. Applications of phototheranostic nanoagents in photodynamic therapy. Nano Res. 2015, 8, 1373–1394.CrossRefGoogle Scholar
  44. [44]
    Ikari, K.; Momohara, S. Bone changes in rheumatoid arthritis. N. Engl. J. Med. 2005, 353, e13.CrossRefGoogle Scholar
  45. [45]
    Marmont, A. M.; Van Lint, M. T.; Gualandi, F.; Bacigalupo, A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. LUPUS 1997, 6, 545–548.CrossRefGoogle Scholar
  46. [46]
    Augello, A.; Tasso, R.; Negrini, S. M.; Cancedda, R.; Pennesi, G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collageninduced arthritis. Arthritis Rheum. 2007, 56, 1175–1186.CrossRefGoogle Scholar
  47. [47]
    Ezashi, T.; Das, P.; Roberts, R. M. Low O2 tensions and the prevention of differentiation of hES cells. Proc. Natl. Acad. Sci. USA 2005, 102, 4783–4788.CrossRefGoogle Scholar
  48. [48]
    Danet, G. H.; Pan, Y.; Luongo, J. L.; Bonnet, D. A.; Simon, M. C. Expansion of human SCID-repopulating cells under hypoxic conditions. J. Clin. Invest. 2003, 112, 126–135.CrossRefGoogle Scholar
  49. [49]
    Morrison, S. J.; Csete, M.; Groves, A. K.; Melega, W.; Wold, B.; Anderson, D. J. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J. Neurosci. 2000, 20, 7370–7376.Google Scholar
  50. [50]
    McInnes, I. B.; Liew, F. Y. Cytokine networks—Towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2005, 1, 31–39.CrossRefGoogle Scholar
  51. [51]
    Wang, F. F.; Zhai, D.; Wu, C. T.; Chang, J. Multifunctional mesoporous bioactive glass/upconversion nanoparticle nanocomposites with strong red emission to monitor drug delivery and stimulate osteogenic differentiation of stem cells. Nano Res. 2016, 9, 1193–1208.CrossRefGoogle Scholar
  52. [52]
    Turner, L.-A.; Dalby, M. J. Nanotopography—Potential relevance in the stem cell niche. Biomater. Sci. 2014, 2, 1574–1594.CrossRefGoogle Scholar
  53. [53]
    Chang, B.; Song, W.; Han, T. X.; Yan, J.; Li, F. P.; Zhao, L. Z.; Kou, H. C.; Zhang, Y. M. Influence of pore size of porous titanium fabricated by vacuum diffusion bonding of titanium meshes on cell penetration and bone ingrowth. Acta Biomater. 2016, 33, 311–321.CrossRefGoogle Scholar
  54. [54]
    Brest, P.; Lapaquette, P.; Souidi, M.; Lebrigand, K.; Cesaro, A.; Vouret-Craviari, V.; Mari, B.; Barbry, P.; Mosnier, J.-F.; Hébuterne, X. et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat. Genet. 2011, 43, 242–245.CrossRefGoogle Scholar
  55. [55]
    Li, Y.; Xu, X. J.; Liang, Y.; Liu, S. Y.; Xiao, H. S.; Li, F.; Cheng, H.; Fu, Z. Z. miR-375 enhances palmitate-induced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression. Int. J. Clin. Exp. Pathol. 2010, 3, 254–264.Google Scholar
  56. [56]
    Poy, M. N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X. S.; MacDonald, P. E.; Pfeffer, S.; Tuschl, T.; Rajewsky, N.; Rorsman, P. et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432, 226–230.CrossRefGoogle Scholar
  57. [57]
    Georgantas, R. W.; Hildreth, R.; Morisot, S.; Alder, J.; Liu, C.-G.; Heimfeld, S.; Calin, G. A.; Croce, C. M.; Civin, C. I. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proc. Natl. Acad. Sci. USA 2007, 104, 2750–2755.CrossRefGoogle Scholar
  58. [58]
    Huang, X. A.; Lin, H. The microRNA regulation of stem cells. Wiley Interdiscip. Rev. Dev. Biol. 2012, 1, 83–95.Google Scholar
  59. [59]
    Garzon, R.; Croce, C. M. MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol. 2008, 15, 352–358.CrossRefGoogle Scholar
  60. [60]
    Neilson, J. R.; Zheng, G. X. Y.; Burge, C. B.; Sharp, P. A. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev. 2007, 21, 578–589.CrossRefGoogle Scholar
  61. [61]
    Selbach, M.; Schwanhäusser, B.; Thierfelder, N.; Fang, Z.; Khanin, R.; Rajewsky, N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455, 58–63.CrossRefGoogle Scholar
  62. [62]
    Costinean, S.; Zanesi, N.; Pekarsky, Y.; Tili, E.; Volinia, S.; Heerema, N.; Croce, C. M. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice. Proc. Natl. Acad. Sci. USA 2006, 103, 7024–7029.CrossRefGoogle Scholar
  63. [63]
    Rodriguez, A.; Vigorito, E.; Clare, S.; Warren, M. V.; Couttet, P.; Soond, D. R.; van Dongen, S.; Grocock, R. J.; Das, P. P.; Miska, E. A. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316, 608–611.CrossRefGoogle Scholar
  64. [64]
    Blüml, S.; Bonelli, M.; Niederreiter, B.; Puchner, A.; Mayr, G.; Hayer, S.; Koenders, M. I.; van den Berg, W. B.; Smolen, J.; Redlich, K. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 2011, 63, 1281–1288.CrossRefGoogle Scholar
  65. [65]
    Zhou, S. Y.; Wang, Y.; Meng, Y.; Xiao, C. Y.; Liu, Z.; Brohawn, P.; Higgs, B. W.; Jallal, B.; Jia, Q.; Qu, B. et al. In vivo therapeutic success of microRNA-155 antagomir in a mouse model of lupus alveolar hemorrhage. Arthritis Rheumatol. 2016, 68, 953–964.CrossRefGoogle Scholar
  66. [66]
    Mizuno, Y.; Yagi, K.; Tokuzawa, Y.; Kanesaki-Yatsuka, Y.; Suda, T.; Katagiri, T.; Fukuda, T.; Maruyama, M.; Okuda, A.; Amemiya, T. et al. miR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. Biochem. Biophys. Res. Commun. 2008, 368, 267–272.CrossRefGoogle Scholar
  67. [67]
    Itoh, T.; Nozawa, Y.; Akao, Y. MicroRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5. J. Biol. Chem. 2009, 284, 19272–19279.CrossRefGoogle Scholar
  68. [68]
    Anderson, C.; Catoe, H.; Werner, R. MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res. 2006, 34, 5863–5871.CrossRefGoogle Scholar
  69. [69]
    Caretti, G.; Di Padova, M.; Micales, B.; Lyons, G. E.; Sartorelli, V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 2004, 18, 2627–2638.CrossRefGoogle Scholar
  70. [70]
    Li, Y.-T.; Chen, S.-Y.; Wang, C.-R.; Liu, M.-F.; Lin, C.-C.; Jou, I. M.; Shiau, A.-L.; Wu, C.-L. Brief Report: Amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223. Arthritis Rheum. 2012, 64, 3240–3245.CrossRefGoogle Scholar
  71. [71]
    Parasuraman, S.; Raveendran, R.; Kesavan, R. Blood sample collection in small laboratory animals. J. Pharmacol. Pharmacother. 2010, 1, 87–93.CrossRefGoogle Scholar

Copyright information

© Tsinghua University Press and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Fawad U. Rehman
    • 1
  • Chunqiu Zhao
    • 1
  • Changyu Wu
    • 1
  • Xiaoqi Li
    • 3
  • Hui Jiang
    • 1
  • Matthias Selke
    • 2
  • Xuemei Wang
    • 1
    Email author
  1. 1.State Key Laboratory of Bioelectronics, School of Biological Science and Medical EngineeringSoutheast UniversityNanjingChina
  2. 2.Department of Chemistry and BiochemistryCalifornia State UniversityLos AngelesUSA
  3. 3.NanJing Foreign Language SchoolNanjingChina

Personalised recommendations